March 27, 2018
Novartis sells stake in consumer healthcare JV to GSK for $13.0 billion
Novartis will sell its 36.5 percent stake in its consumer healthcare joint venture (JV) to GSK for $13.0 billion, it…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Approval
March 27, 2018
Vifor Pharma wants to place its hyperkalaemia treatment in Japan through its partner, Zeria
Vifor Pharma Group has granted Japanese company Zeria Pharmaceutical exclusive rights to develop and commercialise Veltassa, its sodium-free potassium binder approved…
March 26, 2018
BMS gets CHMP’s nod for Opdivo as four-week dosing for skin cancer and treated kidney cancer
Bristol-Myers Squibb said on Monday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…
March 26, 2018
GeNeuro Phase 2 aiming HERVs in multiple sclerosis, first time with benefit shown in clinical trial
GeNeuro’s results from the Phase 2b study of its novel therapeutic treatment of multiple sclerosis (MS) showed a significant, consistent positive…
March 23, 2018
Portola fails to convince EMA that betrixaban is ready for prevention of certain venous thromboembolism in adult patients
Portola will need to provide further clarification to the European Medicines Agency (EMA) for making betrixaban available for the prevention the VTE…
March 23, 2018
Novartis to seek approval for first SPMS (multiple sclerosis) therapy after the positive Phase III results
Novartis could have the first therapy which could delay disability progression secondary progressive multiple sclerosis (SPMS) if it gets the…
March 23, 2018
GSK’s shingles prevention vaccine approved in Europe and Japan
GlaxoSmithKline got the approval for shingles prevention, and post-herpetic neuralgia (PHN) vaccine Shingrix, in Europe, while in Japan it was registered…
March 23, 2018
Novo Nordisk’s type two diabetes treatment for adults approved in japan
The Japanese Ministry of Health, Labour and Welfare has approved Novo Nordisk’s treatment for type 2 diabetes adult patients, new…
March 21, 2018
Sobi launches Ravicti in Europe and advances the care for patients with Urea Cycle Disorders
Swedish Orphan Biovitrum has gained reimbursement for Ravicti, a new therapy option for the treatment of patients with Urea Cycle…
March 20, 2018
Mylan launches Mitomycin, generic cancer drug version of BMS’s Mutamycin
Mylan N.V. has launched its generic version of BMSs oncology drug Mutamycin in USA, called Mitomycin, for which it noted…